TABLE OF CONTENTS

S.No.	Description	Page No.
Chapter 1: Introduction		1
1.1	Introduction	1
1.2	Classification of Impurities	2
1.3	Sources of impurities	2
1.4	Genotoxic impurity and hazard assessment	2
1.5	Theoretical and Practical Aspects of Liquid Chromatography	4
1.6	Theoretical and practical aspects of mass spectrometry	5
1.6.1	Sources	6
1.6.2	Analyzers	8
1.6.3	Detectors	9
1.6.4	Recording of mass spectra	10
1.6.5	LCMS applications	10
1.7	Method of validation of analytical techniques	11
1.7.1	Specificity and Selectivity	12
1.7.2	Precision	12
	1.7.2.1 Repeatability	12
	1.7.2.2 Intermediate precision	12
	1.7.2.3 Reproducibility	12
1.7.3	Linearity	12
1.7.4	Range	13
1.7.5	Accuracy	13
1.7.6	Solution stability	13
1.7.7	Robustness	13
1.7.8	Limit of detection and limit of quantitation	13
1.8	Aim and objective of the present work	14
Chapter 2: Literature Survey		**17**
2.1	Literature survey on atazanavir sulphate and impurities	17
2.2	Literature survey on erlotinib and impurities	18
2.3	Literature survey on imatinib mesylate and its impurities	20

2.4 Literature survey on pantoprazole sodium and its impurities 22
2.5 Literature survey on albendazole and impurities 24
2.6 Literature survey on quantification of genotoxic impurities by GC-MS and LC-MS method 25
Chapter 3: QUANTITATIVE ESTIMATION GENOTOXIC IMPURITY IN ANTIRETROVIRAL DRUG: ATAZANAVIR SULPHATE 27
3.1 Introduction 27
3.2 Experimental 28
3.2.1 Standards and chemicals 28
3.2.2 Preparation of solutions 29
3.2.2.1 Sample preparation 29
3.2.2.2 Preparation of standard BOC epoxide stock solution 29
3.2.2.3 Standard solution preparation 29
3.2.2.4 Preparation of LOD and LOQ solution 29
3.2.2.5 Preparation of accuracy solutions 30
3.2.2.6 Preparation of linearity solutions 30
3.2.2.7 Solution preparation for method precision, intermediate precision and robustness 31
3.2.2.8 Preparation for stability of analytical solution 31
3.2.3 Instrumentation 31
3.3 Results and discussion 32
3.3.1 Method development 32
3.3.2 Operating conditions of LC and MS 32
3.3.3 Validation Study 33
3.3.3.1 Specificity 33
3.3.3.2 Determination of LOD and LOQ 35
3.3.3.3 Recovery Studies 36
3.3.3.4 Linearity 37
3.3.3.5 System suitability 39
3.3.3.6 Precision 39
3.3.3.7 Robustness 40
3.3.3.8 Solution stability 41
3.3.3.9 Application of the method 42

Chapter 4: QUANTIFICATION OF GENOTOXIC IMPURITIES IN ANTI-CANCER DRUGS: ERLOTINIB HYDROCHLORIDE & IMATININB MESYLATE 43

4.1 ERLOTINIB HYDROCHLORIDE 43

4.1.1 Introduction 43

4.1.2 Experimental 44

4.1.2.1 Standards and chemicals 44

4.1.2.2 Preparation of Solutions 45

4.1.2.2.1 Sample preparation 45

4.1.2.2.2 Preparation of standard stock solution 45

4.1.2.2.3 Preparation of standard Solution 45

4.1.2.2.4 Preparation of LOD and LOQ solution 45

4.1.2.2.5 Solution preparation for accuracy 45

4.1.2.2.6 Solution preparation for linearity 46

4.1.2.2.7 Solution preparation for method precision, intermediate precision and robustness study 47

4.1.2.2.8 Preparation for stability of analytical solution 47

4.1.2.3 Instrumentation 47

4.1.3 Discussion on Results 47

4.1.3.1 Method development 47

4.1.3.2 LC-MS/MS operating conditions 47

4.1.3.3 Validation Study 49

4.1.3.3.1 System Suitability 49

4.1.3.3.2 Specificity 49

4.1.3.3.3 Limit of detection (LOD) and limit of quantification (LOQ) 50

4.1.3.3.4 Linearity 50

4.1.3.3.5 Accuracy 52

4.1.3.3.6 Precision 54

4.1.3.3.7 Robustness 54

4.1.3.3.8 Solution stability 56

4.1.3.3.9 Method application 56

4.2. IMATINIB MESYLATE 57

4.2.1 Introduction 57

4.2.2 Experimental 58

4.2.2.1 Standards and chemicals 58

4.2.2.2 Preparation of Solutions 58

4.2.2.2.1 Sample preparation 58

4.2.2.2.2 Preparation of standard IMT-01 stock solution 59

4.2.2.2.3 Preparation of standard Solution 59

4.2.2.2.4 Preparation of LOD and LOQ solution 59

4.2.2.2.5 Preparation of accuracy solutions 59

4.2.2.2.6 Preparation of linearity solutions 60

4.2.2.2.7 Solution preparation for method precision, intermediate precision and robustness study 61

4.2.2.2.8 Preparation for stability of analytical solution 61

4.2.2.3 Instrumentation 61

4.2.3 Results and discussion 61

4.2.3.1 Method development 61

4.2.3.2 Operating conditions of LC/MS/MS 61

4.2.3.3 Validation Study 62

4.2.3.3.1 Specificity 63

4.2.3.3.2 Determination of LOD and LOQ 64

4.2.3.3.3 Recovery studies 64

4.2.3.3.4 Linearity 66

4.2.3.3.5 System Suitability 67

4.2.3.3.6 Precision 67

4.2.3.3.7 Robustness 68

4.2.3.3.8 Solution stability 70

4.2.3.3.9 Application of the method 71

Chapter 5: DETERMINATION OF GENOTOXIC IMPURITIES IN ANTI ULCER DRUG: PANTOPRAZOLE SODIUM SESQUIHYDRATE 72

5.1 Introduction 72
5.2 Experimental 73
5.2.1 Standards and chemicals 73
5.2.2 Preparation of Solutions 74
5.2.2.1 Preparation of standard stock solution 74
5.2.2.2 Preparation of standard solution 74
5.2.2.3 Preparation of LOD and LOQ solution 75
5.2.2.4 Preparation of accuracy solutions 75
5.2.2.5 Preparation of linearity solutions 75
5.2.2.6 Solution preparation for method precision, intermediate precision and robustness study 76
5.2.2.7 Preparation for stability of analytical solution 76
5.2.2.8 Preparation of sample solution 76
5.2.3 Instrumentation 76
5.3 Results and discussion 76
5.3.1 Method development 76
5.3.2 Operating conditions of LC/MS/MS 77
5.3.3 Validation Study 78
5.3.3.1 Specificity 78
5.3.3.2 Limit of detection (LOD) and limit of quantification (LOQ) 79
5.3.3.3 Linearity 80
5.3.3.4 Accuracy 81
5.3.3.5 System Suitability 84
5.3.3.6 Precision 84
5.3.3.7 Robustness 85
5.3.3.8 Solution stability 87
5.3.3.9 Application of the method 88

Chapter 6: EVALUATION OF GENOTOXIC IMPURITIES IN ANTHELMINTIC DRUG: ALBENDAZOLE 89

6.1 Introduction 89

6.2 Experimental 90

6.2.1 Standards and chemicals 90

6.2.2 Preparation of Solutions 91

6.2.2.1 Sample preparation 91

6.2.2.2 Preparation of standard stock solution 91

6.2.2.3 Preparation of standard solution 91

6.2.2.4 Preparation of LOD and LOQ solution 91

6.2.2.5 Preparation of accuracy solutions 91

6.2.2.6 Solution preparation for linearity 92

6.2.2.7 Solution preparation for method precision, intermediate precision and robustness 93

6.2.2.8 Preparation for stability of analytical solution 93

6.2.3 Instrumentation 93

6.3 Discussion on Results 93

6.3.1 Method development 93

6.3.2 LC-MS/MS operating conditions 93

6.3.3 Validation Study 95

6.3.3.1 System Suitability 95

6.3.3.2 Specificity 95

6.3.3.3 Limit of detection (LOD) and limit of quantification (LOQ) 97

6.3.3.4 Linearity 97

6.3.3.5 Accuracy 98

6.3.3.6 Precision 99

6.3.3.7 Robustness 100

6.3.3.8 Solution stability 102

6.3.3.9 Method application 102

Chapter 7: SUMMARY, CONCLUSION AND RECOMMENDATIONS 103

7.1 Summary 103

7.1.1 Quantitative estimation genotoxic impurity in antiretroviral drug: atazanavir sulphate validation study summary 103

7.1.2 Quantification of genotoxic impurities in Anti-Cancer Drugs: Erlotinib hydrochloride & Imatininb mesylate validation summary 104
7.1.2.1 Erlotinib Hydrochloride validation study summary 104
7.1.2.2 Imatinib mesylate validation study summary 105
7.1.3 Determination of genotoxic impurities in Anti Ulcer Drug: Pantoprazole sodium sesquihydrate validation study summary 106
7.1.4 Evaluation of genotoxic impurities in Anthelmintic Drug: Albendazole validation study summary 107
7.2 Conclusions and recommendation 108
References 109
Index 128
List of Publications 130